Drug Discovery News

Related Biotechnology Industry News

• August 2024: Amoneta Diagnostics SAS received Conformité Européene (CE) marking for its APO-Easy genotyping kit in accordance with the European Union (EU) In Vitro Diagnostic Regulation 2017/746 (IVDR). The APO-Easy Genotyping Kit is a ready-to-use qualitative in vitro diagnostic (IVD) test that utilizes real-time polymerase chain reaction (RT-PCR) for the accurate detection of two single-nucleotide polymorphisms (SNPs): rs429358 and rs7412 associated with Alzheimer's disease.
• April 2024: Applied BioCode Inc. unveiled its newest product, the BioCode STI + Resistance Panel for research use only (RUO). This multiplex nucleic acid amplification test is specifically designed to qualitatively identify DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG), along with macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations in a single assay.

• September 2024: Parexel announced the strengthening of its Real World Research (RWR) offering by integrating its Scientific Data Organization and Real World Evidence capabilities. This initiative aims to better meet growing customer needs and enhance the company's ability to provide valuable insights using real-world evidence for clients worldwide.
• August 2024: Eli Lilly announced positive topline results from the SURMOUNT-1 three-year study evaluating the efficacy and safety of tirzepatide for long-term weight management and delay in progression to diabetes in adults with pre-diabetes and obesity or overweight. Tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity or overweight compared to placebo.
• August 2024: Pfizer and BioNTech announced top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals aged 18-64. The combination vaccine met one of its two primary immunogenicity objectives.
• July 2024: Thermo Fisher Scientific announced a partnership with the National Cancer Institute (NCI) to advance the myeloMATCH precision medicine clinical trial. This collaboration utilizes Thermo Fisher's next-generation sequencing technology to rapidly match patients with appropriate clinical trials for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), aiming to accelerate research into new treatments for these conditions.
• July 2024: ICON plc expanded its decentralized clinical trial capabilities by integrating advanced digital health technologies to enhance patient engagement and data collection.

• October 2024: Abcam, now a subsidiary of Danaher Corporation, unveiled a new range of exosome-specific antibodies and kits to support advanced exosome research, focusing on improving detection and characterization methodologies.
• September 2024: Bio-Techne announced the development of a novel exosome-based diagnostic platform aimed at enhancing biomarker discovery and development across multiple disease areas, including oncology and neurodegenerative disorders.
• August 2024: Qiagen expanded its exosome product line by releasing the "miRCURY Exosome Kits," which utilize precipitation methods to efficiently isolate exosomes from various biofluids, facilitating downstream molecular analyses.
• July 2024: Fujifilm Wako Chemicals U.S.A. Corporation launched the "MagCapture™ Exosome Isolation Kit PS Ver.2," an enhanced version aimed at improving the purity and yield of exosome isolation for research applications.
• June 2024: Thermo Fisher introduced the "Exosome Isolation and Analysis Suite," a comprehensive toolkit designed to streamline exosome research by integrating isolation, characterization, and analysis processes.

• August 2024: Adaptimmune Therapeutics PLC was granted approval by the US FDA for TECELRA (afamitresgene autoleucel), marking it as the first engineered cell therapy approved for use in solid tumors and therapy for a rare, soft tissue cancer, synovial sarcoma.
• January 2024: Abbvie and Umoja Biopharma established a strategic collaboration to develop various in-situ generated CAR-T cell therapy candidates in oncology by incorporating Umoja's proprietary VivoVec gene delivery platform.

• July 2023: Pfizer invested USD 25 million in Caribou Biosciences to progress an immune-cloaked allogeneic CAR-T cell therapy, CB-011. The company is currently evaluating the cell therapy in a Phase I CaMMouflage clinical trial for relapsed or refractory multiple myeloma.
• April 2023: InflaRx N.V.'s Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, was granted an Emergency Use Authorization by the United States Food and Drug Administration for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation, or extracorporeal membrane oxygenation.

• January 2024: Rice University of the United States launched the Rice Synthetic Biology Institute, which aims to catalyze collaborative research in synthetic biology and its translation into technologies that benefit society.
• May 2023: GenScript Biotech Corporation, the sponsor of the SynBioBeta Conference in Oakland, California, showcased the latest synthetic biology tools and techniques with strategic partner Allozymes and a diverse line-up of key opinion leaders (KOLs).

• May 2024: Oxford Nanopore Technologies introduced a new Pharmacogenomics (PGx) Beta Programme for advancing personalized medicine with the combination of Twist Bioscience’s next-generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
• February 2024: Nicklaus Children's Hospital in South Florida adopted the next-generation pharmacogenomics technology, Applied Biosystems PharmacoScan Solution and GeneTitan MC Fast Scan Instrument, to develop personalized treatment plans for the patients and reduce the complications from drug interactions and side effects.

• November 2023: QIAGEN NV launched the Microbiome WGS (whole-genome sequencing) SeqSets which is a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research. 
• June 2023: Zymo Research launched its full-length 16S sequencing service offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

• In August 2022, Trivitron Healthcare launched the Center of Excellence with state- of- the art R&D and manufacturing facilities in India. This center will implement research and innovation in the field of genomics and others.
• In July 2022, Replay launched with USD 55 million in seed financing to transform genomic medicine with interlinking technology platforms. The launch is supported by an international syndicate f investors that include KKR, OMX ventures, ARTIS Ventures, and Landsdowne Partners.

• October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.
• October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.